齐拉西酮联合西酞普兰治疗首发精神分裂症患者的效果

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (559 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Ziprasidone and Citalopram in the treatment of patients with firstepisode schizophrenia. Methods A total of 68 patients with first-episode schizophrenia who were treated at Xuzhou Guangci Hospital from January 2018 to January 2020 were selected and divided into the observation group and the control group according to a random number table, with 34 cases in each group. The control group were treated with Ziprasidone, and the observation group were provided with Ziprasidone combined with Citalopram. After 8 weeks of treatment, the treatment effect, executive function and eye movement function of the two groups were observed. Results There were no significant differences in the scores of the positive and negative syndrome scale (PANSS) and total score,eye movement function, or executive function between the two groups before treatment (P＞0.05). After 4 weeks of treatment, the negative symptoms score, psychopathology score and total score of the two groups were lower than before treatment, and the negative symptoms score, psychopathology score and total score of the observation group were lower than those of the control group, the differences were statistically significant (P＜0.05). After 8 weeks of treatment,PANSS scores and total score in both groups were lower than before and 4 weeks after treatment, and PANSS scores and total scores of the observation group were lower than those of the control group, the differences were statistically significant (P＜0.05). After 8 weeks of treatment, the number of eye fixation (NEF) and responsive search score (RSS)scores in the two groups were higher than those before treatment, and discriminant analysis (D) score was lower than that before treatment, the NEF and RSS scores of the observation group were higher than those of the control group,and the D score of the observation group was lower than that of the control group, with statistical significance (P＜0.05).After 8 weeks of treatment, the total number of tests, the number of continuous errors, and the number of random errors of the two group were lower than those before treatment, the number of correct responses and the number of completed classifications were higher than those before treatment and the total number of tests, the number of continuous errors,and the number of random errors in the observation group were lower than that in the control group, the number of correct responses and the number of classification completed in the observation group were higher than those in the control group, with statistical significances (P＜0.05). There was no statistically significant difference in adverse reactions between the two groups (P＜0.05). Conclusion Ziprasidone combined with Citalopram is effective in the treatment of patients with first-episode schizophrenia. It can significantly improve the PANSS score, the executive function and eye movement function of the patients, and has fewer adverse reactions, which can be widely used in clinical.

Key words： Ziprasidone Citalopram First-episode schizophrenia Effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIN Xuefei

Cite this article:

LIN Xuefei. Effect of Ziprasidone combined with Citalopram in the treatment of patients with first-episode schizophrenia[J]. 中国当代医药, 2022, 29(4): 115-119.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I4/115

[1]	林春燕，周红蕊，黎顺成，等.探讨奥氮平对首发精神分裂症伴肥胖患者认知功能、糖脂代谢及相关激素指标水平的影响[J].中国医院药学杂志，2019，39（9）：954-958.
[2]	肖华，姚丽敏，李影，等.男性首发抑郁症与精神分裂症患者事件相关电位P300 的研究[J].临床精神医学杂志，2019，29（6）：385-388.
[3]	郭金涛，郭雅聪，牛好敏，等.艾司西酞普兰治疗帕金森症合并焦虑和抑郁患者的疗效及对其认知功能的影响[J].国际精神病学杂志，2019，46（2）：319-321.
[4]	翟倩，丰雷，张国富.精神分裂症患者的认知功能障碍探讨[J].浙江医学，2019，41（13）：1367-1369，1373.
[5]	陈莉，许军英，刘赛球.抗精神病药物不同治疗时程对精神分裂症患者肾功能的影响[J].中国中西医结合肾病杂志，2019，20（5）：425-427.
[6]	殷美莉，崔维珍.DSM—Ⅳ，ICD—10 及CCMD—2 三种精神分裂症病诊断标准的比较[J].上海精神医学，1996，8（3）：133-135.
[7]	司天梅，杨建中，舒良，等.阳性和阴性症状量表（PANSS，中文版）的信、效度研究[J].中国心理卫生杂志，2004，18（1）：45-47.
[8]	王丽莉，韩永华，朱日升.不同病程的精神分裂症患者探究性眼动分析[J].中国心理卫生杂志，2003，17（10）：702-704.
[9]	刘娜，陆峥，盛建华，等.首次发病的青少年精神分裂症患者执行功能的研究[J].临床精神医学杂志，2013，23（4）：255-257.
[10]	Meade N，Shi L，Meehan SR，et al.Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms：Post-hoc analysis of short-and longterm studies[J].J Psychopharmacol，2020，34（8）：829-838.
[11]	周莉，黄朝红，王琦珠，等.首发女性精神分裂症患者药源性高泌乳素血症的用药分析[J].河北医药，2019，41（9）：1304-1307.
[12]	胡江.齐拉西酮联合氯氮平治疗难治性精神分裂症临床研究[J].山西医药杂志，2019，48（3）：338-341.
[13]	祖鑫，那万秋，陈科，等.艾司西酞普兰治疗老年抑郁症的临床疗效观察[J].临床药物治疗杂志，2019，17（12）：61-65.
[14]	曹保瑞，陈家民，马庆.齐拉西酮联合奥氮平治疗难治性精神分裂症的效果及安全性[J].中国当代医药，2021，28（10）：113-116.
[15]	秦阳，陈思媛，刘炳伦.齐拉西酮和利培酮对女性精神分裂症患者疗效及代谢的影响[J].中国现代医生，2021，59（3）：88-91，96.
[16]	胡伟志，郑荣华，冯文锐.奥氮平联合齐拉西酮治疗精神分裂症患者的效果[J].中外医学研究，2021，19（20）：46-49.
[17]	易湛苗，倪晓凤，刘芳，等.选择性5-羟色胺再摄取抑制剂治疗脑卒中后抑郁患者的循证分析[J].临床药物治疗杂志，2019，17（1）：53-57.
[18]	林晓鸣，余敏，梁晓敏，等.齐拉西酮在氯氮平所致体重增加中的应用[J].中国当代医药，2020，27（12）：132-135.
[19]	Serrita J，Ralevski E，Yoon G，et al.A Pilot Randomized，Placebo-Controlled Trial of Glycine for Treatment of Schizophrenia and Alcohol Dependence[J].J Dual Diagn，2019，15（1）：46-55.
[20]	Simmons A，Carpenter-Conlin J，Bessonova L，et al.Qualitative Clinical Trial Exit Interviews Evaluating Treatment Benefit，Burden，and Satisfaction in Patients with Schizophrenia[J].CNS Spectr，2021，26（2）：156-157.